Transport of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-glycoprotein

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2007-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/jpet.106.116517PMID 17314201
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metabolism And Excretion of the Dipeptidyl Peptidase 4 Inhibitor [14C]Sitagliptin in Humans

  2007influential reference
• Disposition of the Dipeptidyl Peptidase 4 Inhibitor Sitagliptin in Rats and Dogs

  2007cited by this paper
• Effect of a Single Cyclosporine Dose on the Single‐Dose Pharmacokinetics of Sitagliptin (MK‐0431), a Dipeptidyl Peptidase‐4 Inhibitor, in Healthy Male Subjects

  2007cited by this paper
• Human renal organic anion transporters: characteristics and contributions to drug and drug metabolite excretion.

  2006cited by this paper
• Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

  2006cited by this paper
• Drugdrug interactions involving membrane transporters in the human kidney

  2006cited by this paper
• Renal Tubular Drug Transporters

  2006influential reference
• The MATE proteins as fundamental transporters of metabolic and xenobiotic organic cations.

  2006cited by this paper
• Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants.

  2006cited by this paper
• Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes

  2006cited by this paper
• Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects.

  2006cited by this paper
• Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport

  2005cited by this paper
• A Species Difference in the Transport Activities of H2 Receptor Antagonists by Rat and Human Renal Organic Anion and Cation Transporters

  2005cited by this paper
• (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

  2005cited by this paper
• Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs.

  2005cited by this paper
• MK-431 (Merck).

  2005cited by this paper
• Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double‐blind, placebo‐controlled studies with single oral doses

  2005cited by this paper
• Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays

  2005cited by this paper
• Molecular physiology of urate transport.

  2005cited by this paper
• Pharmacokinetics and bioavailability of indapamide — A new antihypertensive drug

  2004cited by this paper
• Peptide transporters: structure, function, regulation and application for drug delivery.

  2004influential reference
• Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney.

  2004cited by this paper
• Transporters and renal drug elimination.

  2004cited by this paper
• Molecular and cellular physiology of renal organic cation and anion transport.

  2004cited by this paper
• Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.

  2001cited by this paper
• Role of P-glycoprotein in drug disposition.

  2000cited by this paper
• Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.

  2000cited by this paper
• The glucagon-like peptides.

  1999cited by this paper
• The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1.

  1999influential reference
• Molecular Physiology

  1998cited by this paper
• A Pharmacodynamic and Pharmacokinetic Comparison of Intravenous Quinaprilat and Oral Quinapril

  1996cited by this paper
• Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients

  1995cited by this paper
• Pharmacokinetics of gabapentin in subjects with various degrees of renal function

  1994cited by this paper
• Selectivity of the cimetidine-induced alterations in the renal handling of organic substrates in humans. Studies with anionic, cationic and zwitterionic drugs.

  1986cited by this paper
• Pharmacokinetics of ibuprofen.

  1984cited by this paper
• Pharmacokinetics of probenecid following oral doses to human volunteers.

  1982cited by this paper
• [Clinical pharmacokinetics].

  1976cited by this paper
• The Pharmacological Basis of Therapeutics

  1966cited by this paper
• The Pharmacological Basis of Therapeutics

  1941cited by this paper
• J Am Soc Nephrol 13: 866–874, 2002 Gene Expression Levels and Immunolocalization of Organic Ion Transporters in the Human Kidney

  year unknowninfluential reference

• Role of Transport Proteins for the Renal Handling of L-Arginine and Related Derivatives

  2025cites this paper
• Identification of selective substrates and inhibitors of the major human renal uptake transporters.

  2025cites this paper
• Transporter-Mediated Interactions Between Uremic Toxins and Drugs: A Hidden Driver of Toxicity in Chronic Kidney Disease

  2025cites this paper
• Characterization of small molecule drug clearance mechanisms using in vitro and in vivo approaches in drug discovery and development

  2025cites this paper
• Sitagliptin elevates plasma and CSF incretin levels following oral administration to nonhuman primates: relevance for neurodegenerative disorders

  2024cites this paper
• Organic anion transporting polypeptides: Pharmacology, toxicology, structure, and transport mechanisms.

  2024cites this paper
• Bempedoic Acid, the First-in-Class Oral ATP Citrate Lyase Inhibitor with Hypocholesterolemic Activity: Clinical Pharmacology and Drug–Drug Interactions

  2024cites this paper
• Innovative Approaches to Optimize Clinical Transporter Drug–Drug Interaction Studies

  2024cites this paper
• A web-based scoping review assessing the influence of smoking and smoking cessation on antidiabetic drug meabolism: implications for medication efficacy

  2024cites this paper
• DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson’s disease

  2024cites this paper
• Characterization of Elimination Pathways and the Feasibility of Endogenous Metabolites as Biomarkers of Organic Anion Transporter 1/3 Inhibition in Cynomolgus Monkeys

  2023cites this paper
• The simultaneous quantification of Sitagliptin and Irbesartan in rat plasma using the validated LC-MS/MS method is applied to a pharmacokinetic study.

  2023cites this paper
• In vitro validation of an in vivo phenotyping drug cocktail for major drug transporters in humans.

  2023cites this paper
• Vesicles of yeast cell wall-sitagliptin to alleviate neuroinflammation in Alzheimer's disease.

  2022cites this paper
• Bile Acid–Drug Interaction via Organic Anion-Transporting Polypeptide 4C1 Is a Potential Mechanism of Altered Pharmacokinetics of Renally Excreted Drugs

  2022cites this paper
• Special Section on New Era of Transporter Science — Minireview Emerging Roles of the Human Solute Carrier 22 Family S

  2022cites this paper
• Characterization of Clofazimine as a Potential Substrate of Drug Transporter

  2022cites this paper
• Discovery of the First Non-cGMP Mimetic Small Molecule Activators of cGMP-Dependent Protein Kinase 1 α (PKG1α).

  2021cites this paper
• Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Sitagliptin phosphate monohydrate.

  2021cites this paper
• The Prescription of Drugs That Inhibit Organic Anion Transporters 1 or 3 Is Associated with the Plasma Accumulation of Uremic Toxins in Kidney Transplant Recipients

  2021cites this paper
• GENETICALLY MODIFIED RENAL PROXIMAL TUBULE EPITHELIAL CELLS

  2021cites this paper
• Hypoglycemia Associated With Drug–Drug Interactions in Patients With Type 2 Diabetes Mellitus Using Dipeptidylpeptidase-4 Inhibitors

  2021cites this paper
• Urate transport in health and disease.

  2021cites this paper
• Drug–drug interaction potential and clinical pharmacokinetics of enerisant, a novel potent and selective histamine H3 receptor antagonist

  2021cites this paper
• Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters

  2021cites this paper
• Intestinal Absorption of Alogliptin Is Mediated by a Fruit-Juice-Sensitive Transporter.

  2021cites this paper
• Clozapine affects the pharmacokinetics of risperidone and inhibits its metabolism and P-glycoprotein-mediated transport in vivo and in vitro: A safety attention to antipsychotic polypharmacy with clozapine and risperidone.

  2021cites this paper
• Modulation of Urate Transport by Drugs

  2021cites this paper
• Emerging Roles of the Human Solute Carrier 22 Family

  2021cites this paper
• Role of OATP4C1 in Renal Handling of Remdesivir and its Nucleoside Analog GS-441524: The First Approved Drug for Patients with COVID-19.

  2021cites this paper
• Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking

  2021influential citation
• A Physiologically‐Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP‐1 and GIP and the DPP4 Inhibitor Sitagliptin

  2020cites this paper
• Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor

  2020cites this paper
• Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients

  2020cites this paper
• Over-the-counter analgesics during pregnancy: a comprehensive review of global prevalence and offspring safety.

  2020cites this paper
• Transport of L-Arginine Related Cardiovascular Risk Markers

  2020cites this paper
• Structural Insights into the Atomistic Mechanisms of Uric Acid Recognition and Translocation of Human Urate Anion Transporter 1

  2020cites this paper
• Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects

  2020cites this paper
• In Vitro Evaluation of the Drug Interaction Potential of Doravirine

  2019cites this paper
• Drug interactions of dipeptidyl peptidase 4 inhibitors involving CYP enzymes and P-gp efflux pump

  2019cites this paper
• A Clinical Drug‐Drug Interaction Study Assessing a Novel Drug Transporter Phenotyping Cocktail With Adefovir, Sitagliptin, Metformin, Pitavastatin, and Digoxin

  2019cites this paper
• A HILIC-MS/MS assay for the quantification of metformin and sitagliptin in human plasma and urine: A tool for studying drug transporter perturbation.

  2019cites this paper
• Roles of Renal Drug Transporter in Drug Disposition and Renal Toxicity.

  2019cites this paper
• Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes

  2019influential citation
• Transport of Bupropion and its Metabolites by the Model CHO and HEK293 Cell Lines.

  2019cites this paper
• Organic Anion Transporting Polypeptide (OATP) transporter expression, localization and function in the human intestine.

  2019cites this paper
• Assessment of Pharmacokinetic Drug-Drug Interactions in Humans: In Vivo Probe Substrates for Drug Metabolism and Drug Transport Revisited.

  2019cites this paper
• Role of transporters in the disposition of a novel β-lactamase inhibitor: relebactam (MK-7655).

  2019cites this paper
• Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition

  2018cites this paper
• Geschlechtsabhängige Expression renaler und hepatischer Transporter für organische Anionen und Kationen

  2018cites this paper
• Drug-Drug Interactions: Influence of verapamil on the pharmacokinetics of sitagliptin in rats and Ex vivo models

  2018cites this paper
• 10.25 – Uptake Transporters

  2018cites this paper
• Interaction Studies between Sitagliptin Phosphate and Atorvastatin Calcium in Streptozotocin Induced Chronic Type II Diabetes Mellitus Rat Model

  2018cites this paper
• Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects

  2018cites this paper
• TRANSPORTADORES CELULARES DE DROGAS. EL VIAJE DE LOS ANTIDIABÉTICOS ORALES POR EL ORGANISMO

  2018cites this paper
• Eugenia jambolana extract reduces the systemic exposure of Sitagliptin and improves conditions associated with diabetes: A pharmacokinetic and a pharmacodynamic herb-drug interaction study

  2018cites this paper
• Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males

  2018cites this paper
• Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance

  2018cites this paper
• Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus.

  2017cites this paper
• Age-associated differences in transporter gene expression in kidneys of male rats.

  2017cites this paper
• Renal Drug Transporters and Drug Interactions

  2017cites this paper
• Potential Drug Interactions Mediated by Renal Organic Anion Transporter OATP4C1

  2017cites this paper
• Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations

  2017cites this paper
• The role of organic anion transporting polypeptides in drug absorption, distribution, excretion and drug-drug interactions

  2017cites this paper
• Organic Anion Transporter 2: An Enigmatic Human Solute Carrier

  2017cites this paper
• Recent advance in the pharmacogenomics of human Solute Carrier Transporters (SLCs) in drug disposition☆

  2017cites this paper
• Cyclin B1 mediates the effect of UCHL1 in promoting cell cycle progression in uterine papillary serous carcinoma

  2017cites this paper
• Kidney-on-a-Chip: Technologies for Studying Pharmacological and Therapeutic Approaches to Kidney Repair

  2017cites this paper
• Extended Clearance Classification System (ECCS) and its Utility in Predicting Clearance Rate-Determining Step in Drug Discovery

  2017cites this paper
• Early alterations of bile canaliculi dynamics and the ROCK/MLCK pathway are characteristics of drug-induced intrahepatic cholestasis

  2016cites this paper
• Expression of P-glycoprotein in excised human nasal mucosa and optimized models of RPMI 2650 cells.

  2016cites this paper
• A concise review of the bioanalytical methods for the quantitation of sitagliptin, an important dipeptidyl peptidase-4 (DPP4) inhibitor, utilized for the characterization of the drug.

  2016cites this paper
• CELL MODELS FOR STUDYING THE INTERPLAY BETWEEN CONJUGATIVE METABOLISM AND EFFLUX TRANSPORTERS: ESTABLISHING UGT1A1, UGT2B7 AND MRP3 TRANSFECTED MDCK CELL LINES

  2016cites this paper
• Altération de la dynamique des canalicules biliaires in vitro : une nouvelle approche de la prédiction de la cholestase intrahépatique d'origine médicamenteuse

  2016cites this paper
• Organic Anion Transporter 2 (OAT2): An Enigmatic Human Solute Carrier

  2016cites this paper
• Mechanism of high affinity inhibition of the human urate transporter URAT1

  2016cites this paper
• Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study

  2016cites this paper
• Enjoy the best of all worlds with human telomerase reverse transcriptase (hTERT)-immortalized Primary Cells from ATCC

  2016cites this paper
• Early Alterations of Bile Canaliculi Dynamics and the Rho Kinase/Myosin Light Chain Kinase Pathway Are Characteristics of Drug-Induced Intrahepatic Cholestasis

  2016cites this paper
• Probenecid protects against oxygen-glucose deprivation injury in primary astrocytes by regulating inflammasome activity.

  2016cites this paper
• Nonclinical Pharmacokinetics, Disposition, and Drug-Drug Interaction Potential of a Novel d-Amino Acid Peptide Agonist of the Calcium-Sensing Receptor AMG 416 (Etelcalcetide)

  2016cites this paper
• Organic Anion Transporter 2 ( OAT 2 ) : An Enigmatic Human Solute Carrier

  2016cites this paper
• Physiological scaling factors and mechanistic models for prediction of renal clearance from in vitro data

  2016cites this paper
• A Human Renal Proximal Tubule Cell Line with Stable Organic Anion Transporter 1 and 3 Expression Predictive for Antiviral-Induced Toxicity

  2016cites this paper
• The Role of Transporters in Drug Delivery and Excretion

  2016cites this paper
• Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure

  2016influential citation
• Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)

  2015cites this paper
• PharmGKB summary: ibuprofen pathways

  2015cites this paper
• Multiple system atrophy : a translational approach Characterization of the insulin/IGF-1 signaling pathway

  2015cites this paper
• Next generation sequencing of sex-specific genes in the livers of obese ZSF1 rats.

  2015cites this paper
• Sex-Differences in Renal Expression of Selected Transporters and Transcription Factors in Lean and Obese Zucker Spontaneously Hypertensive Fatty Rats

  2015cites this paper
• A Pharmacokinetic/Pharmacodynamic Drug–Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs

  2015cites this paper
• Sunitinib–ibuprofen drug interaction affects the pharmacokinetics and tissue distribution of sunitinib to brain, liver, and kidney in male and female mice differently

  2015cites this paper
• The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.

  2015cites this paper
• Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development

  2014cites this paper
• Evaluation Vitro In Inhibition of Major Drug Transporters : an Clinical Drug Interactions through Raltegravir Has a Low Propensity To Cause

  2014cites this paper
• Organic anion-transporting polypeptides: a novel approach for cancer therapy

  2014cites this paper
• Quantification of intracellular and extracellular digoxin and ouabain by liquid chromatography/electrospray ionization tandem mass spectrometry.

  2014cites this paper
• Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development

  2014cites this paper
• Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development

  2014cites this paper